Outcomes | No. of studies | Pts receiving ILNSI (no.) | Pts receiving ILNPI (no.) | All pts. (no.) | HR/OR (95% CI) | P | Study heterogeneity | |||
---|---|---|---|---|---|---|---|---|---|---|
χ2 | df | I2 (%) | P | |||||||
Subgroup analysis | ||||||||||
 Studies using IMRT | ||||||||||
  3-year OS | 2 | 360 | 456 | 816 | 1.10 (0.69,1.74) | 0.68 | 0.20 | 1 | 0 | 0.65 |
  3-year RRFS | 3 | 414 | 556 | 970 | 1.11 (0.50,2.49) | 0.80 | 1.26 | 2 | 0 | 0.53 |
  3-year DFS | 2 | 243 | 457 | 700 | 0.92 (0.64,1.33) | 0.67 | 26 | 1 | 26 | 0.24 |
  3-year DMFS | 3 | 414 | 556 | 970 | 0.97 (0.62,1.51) | 0.88 | 3.85 | 2 | 48 | 0.15 |
  ILN recurrence | 3 | 414 | 556 | 970 | 1.44 (0.35,5.95) a | 0.62 | 3.12 | 2 | 36 | 0.21 |
 Studies using 2D-RT | ||||||||||
  3-year OS | 2 | 176 | 207 | 383 | 1.35 (0.79,2.30) | 0.27 | 0.29 | 1 | 0 | 0.59 |
  3-year DFS | 2 | 176 | 207 | 383 | 1.41 (0.87,2.30) | 0.17 | 0.15 | 1 | 0 | 0.70 |
  ILN recurrence | 2 | 176 | 207 | 383 | 1.17 (0.16,8.32) a | 0.88 | 0.02 | 1 | 0 | 0.90 |
Sensitivity analysis | ||||||||||
 English publications | ||||||||||
  3-year OS | 4 | 602 | 634 | 1236 | 1.07 (0.73,1.57) | 0.73 | 1.69 | 3 | 0 | 0.64 |
  3-year RRFS | 5 | 571 | 1128 | 1699 | 1.27 (0.69,2.33) | 0.44 | 2.48 | 4 | 0 | 0.65 |
  3-year DFS | 2 | 243 | 457 | 700 | 0.92 (0.64,1.33) | 0.67 | 26 | 1 | 26 | 0.24 |
  3-year DMFS | 6 | 693 | 835 | 1528 | 1.00 (0.69,1.44) | 0.99 | 3.98 | 5 | 0 | 0.55 |
  ILN recurrence | 7 | 761 | 1377 | 2138 | 0.95 (0.44,2.09) a | 0.91 | 5.64 | 6 | 0 | 0.46 |
 High-quality studies | ||||||||||
  3-year OS | 4 | 519 | 652 | 1171 | 1.02 (0.69,1.52) | 0.92 | 1.44 | 3 | 0 | 0.70 |
  3-year RRFS | 5 | 488 | 1146 | 1634 | 1.29 (0.71,2.37) | 0.41 | 2.99 | 4 | 0 | 0.56 |
  3-year DFS | 3 | 331 | 574 | 905 | 0.95 (0.67,1.34) | 0.78 | 1.58 | 2 | 0 | 0.45 |
  3-year DMFS | 4 | 485 | 635 | 1120 | 0.92 (0.62,1.36) | 0.68 | 1.49 | 3 | 0 | 0.69 |
  ILN recurrence | 6 | 641 | 1291 | 1932 | 1.05 (0.46,2.42) a | 0.90 | 4.14 | 5 | 0 | 0.53 |
 Studies matched for T category | ||||||||||
  3-year OS | 5 | 689 | 811 | 1500 | 1.13 (0.82,1.55) | 0.44 | 1.41 | 4 | 0 | 0.84 |
  3-year RRFS | 5 | 570 | 1215 | 1785 | 1.20 (0.63,2.29) | 0.54 | 2.81 | 4 | 0 | 0.59 |
  3-year DFS | 4 | 419 | 664 | 1083 | 1.08 (0.80,1.44) | 0.62 | 3.37 | 3 | 11 | 0.34 |
  3-year DMFS | 5 | 604 | 805 | 1409 | 0.98 (0.67,1.44) | 0.93 | 3.87 | 4 | 0 | 0.42 |
  ILN recurrence | 7 | 811 | 1453 | 2264 | 1.06 (0.49,2.33) a | 0.88 | 3.39 | 6 | 0 | 0.76 |
 Studies detecting LN metastases mainly by MRI | ||||||||||
  3-year OS | 4 | 602 | 634 | 1236 | 1.07 (073,1.57) | 0.73 | 1.69 | 4 | 0 | 0.64 |
  3-year RRFS | 4 | 503 | 586 | 1089 | 1.37 (0.68,2.76) | 0/38 | 2.31 | 3 | 0 | 0.51 |
  3-year DFS | 4 | 419 | 664 | 1083 | 1.08 (0.80,1.44) | 0.62 | 3.37 | 3 | 11 | 0.34 |
  3-year DMFS | 6 | 693 | 835 | 1528 | 1.00 (0.69,1.44) | 0.99 | 3.98 | 5 | 0 | 0.55 |
  ILN recurrence | 6 | 693 | 835 | 1528 | 1.05 (0.37,2.96) a | 0.93 | 5.58 | 5 | 10 | 0.35 |